Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
The Risky Business of Limiting Medicaid Access to Sovaldi

Partially because of its high cost, nearly half the states are restricting Medicaid patients' access to an effective new hepatitis C drug. Experts say there’s no question lawsuits will come.

Published
16 hours ago
From
Governing
Nearly Half of Surveyed US Specialists Expect to Prescribe Gilead's Sofosbuvir / Ledipasvir Regimen Near-Term for Hepatitis C Infections

Analysis of surveyed specialists' near-term prescribing intent indicates that nearly one in every four actively treated genotype 1 patients will be prescribed the sofosbuvir/ledipasvir regimen in the next six months. However, the on-treatment patient shares for the off-label Olysio (Janssen) and Sovaldi combination regimen are expected to remain stable over this period.

Published
17 hours ago
From
Decision Resources Group press release
Expanded harm reduction provision achieves impressive reductions in HCV incidence among PWID in Scotland

Implementation of comprehensive harm reduction policies has achieved impressive reductions in incidence of hepatitis C virus (HCV) infections among people who inject drugs (PWID) in Scotland, research publish

Published
20 August 2014
By
Michael Carter
Britain Has No Problem Paying for Expensive Hepatitis C Drugs

The U.K.’s decision to recommend Sovaldi was far from a sure thing. But once the National Institute for Health and Care Excellence was convinced that Sovaldi is cost-effective, the decision to pay for it is simple, because one entity pays for all the medical care in the U.K. If treating a patient with costly drugs now prevents a more expensive liver transplant in 15 years, that savings accrues to the National Health Service—and ultimately to British taxpayers.

Published
19 August 2014
From
Businessweek
PegLambda discontinued by BMS

We have concluded that given the very promising developments in HCV in terms of emerging all-oral therapeutic options, Lambda would no longer fulfill the unmet need that we had envisioned upon initiation of the clinical trials.

Published
18 August 2014
From
EATG
Emergent HCV epidemic among young, non-urban people who inject drugs in the United States

Incidence of acute hepatitis C virus (HCV) infection increased significantly among young, non-urban people who inject drugs in the United States between 2006 and 2012, investigators report in

Published
18 August 2014
By
Michael Carter
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection.

Published
18 August 2014
From
Achillion press release
NICE consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

In further draft guidance NICE has recommended sofosbuvir (Sovaldi, Gilead Sciences) as a treatment option for some people with chronic hepatitis C. The positive recommendation follows receipt of additional information about the drug’s cost effectiveness from the manufacturer.

Published
15 August 2014
From
NICE
UK cost body backs pricey Gilead hepatitis pill for some patients

Carole Longson, director of the NICE Centre for Health Technology Evaluation, said on Friday it was now provisionally recommending Sovaldi, also known as sofosbuvir, as a cost-effective treatment for some people with chronic hepatitis C.

Published
15 August 2014
From
Reuters
OTP patients, ideal for new hepatitis C medication, put on bottom of list by payers

Sovaldi, approved by the Food and Drug Administration (FDA) last year for the treatment of chronic hepatitis C (HCV), has a success rate better than 90 percent, and is ideal for use in opioid treatment programs (OTPs), yet payers are balking at covering it for patients who have a history of a substance use disorder (SUD), ADAW has learned.

Published
14 August 2014
From
Alcohol & Drug Abuse Weekly
← First12345...140Next →

Filter by country